Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Clinical trial NCT05609968 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05609968
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-06
- Primary completion
- 2027-01-12
- Enrollment
- 614
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.